Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Drug Maker To Seek New Trial For Parkinson’s Drug Approval

This article was originally published in PharmAsia News

Executive Summary

Japan's Kyowa Hakko Kirin says it plans to put its Parkinson's disease drug through Phase III clinical trials later this year. The drug, KW-6002 (istradefylline), targets the brain's adenosine A2A receptor to prevent destruction of dopamine. The drug is to be used in conjunction with current treatments. The company failed in a bid to get U.S. approval last year when the FDA said it needed more data. Now that Phase II trials in Japan have been conducted, the company feels it is time to make a new approval attempt and is considering a license to another drug maker. (Click here for more - a subscription may be required

You may also be interested in...

Stada UK Partners With Diabetes Charity To Promote Foot Health

Diabetes-related foot amputations are on the rise in the UK. Stada through its UK subsidiary Thornton & Ross is partnering with Diabetes UK to promote foot health and the benefits of using its leading OTC foot-care brand, Flexitol. 

Coronavirus Update: Moderna Still Confident Of November Readout

The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.

Latest European Commission Document Focuses On New Rapid Antigen Tests for COVID-19

With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts